Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721045 · ClinicalTrials.gov registry record · Phase 2
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
A Phase 2 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00721045 is a Phase 2 study that has completed, run by Mesoblast. The registered enrollment target is 60 participants.
The verdict
NCT00721045, a Phase 2 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a dose-ranging clinical study to evaluate the feasibility, safety, and tolerability of 3 different doses of immunoselected, culture expanded, nucleated, allogeneic MPCs in subjects who have cardiomyopathy of both ischemic and idiopathic etiology.
Interventions
- BIOLOGICAL Mesenchymal Precursor Cells (MPCs)
- PROCEDURE standard-of-care treatment with mock mapping and injection procedures.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721045
The ClinicalTrials.gov registry entry for NCT00721045 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mesenchymal Precursor Cells (MPCs) is the first listed.
NCT00721045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721045 about?
NCT00721045 is a clinical study titled "A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure". This is a dose-ranging clinical study to evaluate the feasibility, safety, and tolerability of 3 different doses of immunoselected, culture expanded, nucleated, allogeneic MPCs in subjects who have cardiomyopathy of both ischemic and idiopathic etiology.
What is the current status of trial NCT00721045?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-08. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00721045?
The interventions under investigation include: Mesenchymal Precursor Cells (MPCs) (BIOLOGICAL), standard-of-care treatment with mock mapping and injection procedures. (PROCEDURE).
Who is sponsoring clinical trial NCT00721045?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.